•  
  •  
  •  

SomaGenics is a privately held biotech company with offices and laboratories located in Santa Cruz, CA. We specialize in small RNA technologies, including innovative RNAi-based therapeutics using sshRNA molecules, and diagnostics/biomarker detection of small or fragmented RNA, including microRNAs.

learn more

RNA Leaders

We focus on developing novel RNA-centered approaches to addressing unmet medical needs. SomaGenics' research and development has been supported by over $20M in competitive grants and it is our policy to publish the results of our efforts in respected peer-reviewed journals. Our staff includes internationally recognized leaders in RNA research and technology development. Learn more...

more about SomaGenics

Latest from SomaGenics

 

Somagenics Awarded 2-Year NIH grant to develop NGS microRNA Library Technology

SANTA CRUZ, Calif., April 2015 – Somagenics has been awarded a two-year NIH grant to develop its novel RealSeq™–T technology for targeted next-generation sequencing (NGS) of small RNAs such as...

Read more

Three SomaGenics Publications Demonstrate Successful Inhibition of the Hepatitis C Virus by Therapeutic sshRNA™ and Confirm Mechanism of Action

SANTA CRUZ, Calif., Dec. 19, 2014 — SomaGenics and collaborators have published exciting results on the efficacy of RNA interference (RNAi) therapeutics against the hepatitis C virus (HCV) based on the...

Read more

SomaGenics Receives $2,275,000 in NIH Funding to Develop its RNAi Therapeutics and microRNA Technologies

SANTA CRUZ, Calif., Dec. 18, 2014 – SomaGenics has recently been awarded $2,275,000 in Small Business Innovation Research (SBIR) grants from the NIH to further develop and expand its RNA-based technologies...

Read more

SomaGenics Awarded Four Patents Spanning Its miRNA and RNAi Programs

SANTA CRUZ, Calif., Dec. 16, 2014 – SomaGenics, Inc. has had four patents covering various aspects of its small RNA platform technologies issued or allowed by the US and European...

Read more